Stina Syvänen
Stina Syvänen
Researcher, Public Health and Caring Sciences
Verifierad e-postadress på
Citeras av
Citeras av
On the rate and extent of drug delivery to the brain
M Hammarlund-Udenaes, M Fridén, S Syvänen, A Gupta
Pharmaceutical research 25 (8), 1737-1750, 2008
Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport
S Syvänen, Ö Lindhe, M Palner, BR Kornum, O Rahman, B Långström, ...
Drug metabolism and disposition 37 (3), 635-643, 2009
Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer’s disease
D Sehlin, XT Fang, L Cato, G Antoni, L Lannfelt, S Syvänen
Nature communications 7 (1), 1-11, 2016
Advances in PET imaging of P-glycoprotein function at the blood-brain barrier
S Syvänen, J Eriksson
ACS chemical neuroscience 4 (2), 225-237, 2013
Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood–brain barrier can be studied with PET
S Syvänen, G Blomquist, M Sprycha, AU Höglund, M Roman, O Eriksson, ...
Neuroimage 32 (3), 1134-1141, 2006
Bivalent brain shuttle increases antibody uptake by monovalent binding to the transferrin receptor
G Hultqvist, S Syvänen, XT Fang, L Lannfelt, D Sehlin
Theranostics 7 (2), 308, 2017
Pharmacokinetic consequences of active drug efflux at the blood–brain barrier
S Syvänen, R Xie, S Sahin, M Hammarlund-Udenaes
Pharmaceutical research 23 (4), 705-717, 2006
Blood–brain barrier penetration of zolmitriptan—modelling of positron emission tomography data
M Bergström, R Yates, A Wall, M Kågedal, S Syvänen, B Långström
Journal of pharmacokinetics and pharmacodynamics 33 (1), 75-91, 2006
Delineating amyloid plaque associated neuronal sphingolipids in transgenic Alzheimer’s disease mice (tgArcSwe) using MALDI imaging mass spectrometry
I Kaya, D Brinet, W Michno, S Syvänen, D Sehlin, H Zetterberg, ...
ACS chemical neuroscience 8 (2), 347-355, 2017
[11 C] phenytoin revisited: synthesis by [11 C] CO carbonylation and first evaluation as a P-gp tracer in rats
J Verbeek, J Eriksson, S Syvänen, M Labots, ECM de Lange, RA Voskuyl, ...
EJNMMI research 2 (1), 1-11, 2012
Specific uptake of an amyloid-β protofibril-binding antibody-tracer in AβPP transgenic mouse brain
K Magnusson, D Sehlin, S Syvänen, MM Svedberg, O Philipson, ...
Journal of Alzheimer's Disease 37 (1), 29-40, 2013
(R)-[11 C] Verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus
S Syvänen, G Luurtsema, CFM Molthoff, AD Windhorst, MC Huisman, ...
BMC medical imaging 11 (1), 1-16, 2011
Pharmacokinetics of P‐glycoprotein inhibition in the rat blood‐brain barrier
S Syvänen, A Hooker, O Rahman, H Wilking, G Blomquist, B Långström, ...
Journal of pharmaceutical sciences 97 (12), 5386-5400, 2008
(R)-[11C] PK11195 brain uptake as a biomarker of inflammation and antiepileptic drug resistance: evaluation in a rat epilepsy model
RM Bogdanović, S Syvänen, C Michler, V Russmann, J Eriksson, ...
Neuropharmacology 85, 104-112, 2014
Using PET studies of P-gp function to elucidate mechanisms underlying the disposition of drugs
S Syvanen, M Hammarlund-Udenaes
Current topics in medicinal chemistry 10 (17), 1799-1809, 2010
Probing amyloid‐β pathology in transgenic Alzheimer's disease (tgArcSwe) mice using MALDI imaging mass spectrometry
L Carlred, W Michno, I Kaya, P Sjövall, S Syvänen, J Hanrieder
Journal of neurochemistry 138 (3), 469-478, 2016
Altered GABAA receptor density and unaltered blood–brain barrier transport in a kainate model of epilepsy: an in vivo study using 11C-flumazenil and PET
S Syvänen, M Labots, Y Tagawa, J Eriksson, AD Windhorst, ...
Journal of Nuclear Medicine 53 (12), 1974-1983, 2012
A bispecific Tribody PET radioligand for visualization of amyloid-beta protofibrils–a new concept for neuroimaging
S Syvänen, XT Fang, G Hultqvist, SR Meier, L Lannfelt, D Sehlin
Neuroimage 148, 55-63, 2017
[11C] quinidine and [11C] laniquidar PET imaging in a chronic rodent epilepsy model: impact of epilepsy and drug-responsiveness
S Syvänen, V Russmann, J Verbeek, J Eriksson, M Labots, C Zellinger, ...
Nuclear medicine and biology 40 (6), 764-775, 2013
Astroglial responses to amyloid-beta progression in a mouse model of Alzheimer’s disease
M Olsen, X Aguilar, D Sehlin, XT Fang, G Antoni, A Erlandsson, ...
Molecular Imaging and Biology 20 (4), 605-614, 2018
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20